Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EBIN melanoma sequencing trial
2023-505376-30-00Phase 2Authorised
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Jun 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 7
01
Overview
Phase 2, randomised, open-label trial of ipilimumab, nivolumab, encorafenib and binimetinib in melanoma, cutaneous melanoma (CM) and mucosal melanoma (MM), sponsored by European Organisation for Research and Treatment of Cancer. Primary endpoint: Progression-free survival. Planned start Jun 2024; status: authorised.
02
Drugs
03
Conditions
melanomacutaneous melanoma (CM)mucosal melanoma (MM)
Beyond the preview
Go deeper on 2023-505376-30-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505376-30-00.